Search results for 37

Anti-THIK-2 K+ channel Antibody (N468/37), AntibodySystem, RHN18601

Coagulation factor XII, Human, mAb 10-11-37, Hycult Biotech, HM2322

Monoclonal antibody 10-11-37 recognizes Coagulation Factor XII (FXII, Hageman factor). FXII is a serine protease and plays a role in blood coagulation, fibrinolysis, kinin and complement systems. The protein is the zymogen of the serine protease factor XIIa (FXIIa). FXII is converted to FXIIa through autoactivation induced by contact to charged surfaces, also known as the plasma contact system. FXII is predominantly synthesized in the liver and is composed of fibronectin type I and II domains, two epidermal growth factor-like domains, a kringle region, a proline-rich domain and a catalytic domain. Its molecular weight is approximately 80kDa on SDS-PAGE gel electroforeses. The protein circulates in the plasma at a concentration of 30-35 μg/ml. FXII forms the plasma contact system together with high molecular weight kininogen and plasma kalikrein. FXII autoactivates when these three proteins form a complex on negatively charged nonphysiological surfaces, like inorganic surfaces (eg silicon tubes) or macromolecular organic surfaces (eg heparin) bound to the surface of different cell types, including endothelial cells, platelets and neutrophils. It can trigger blood coagulation and generation of proinflammatory bradykinin. After surface complexation, FXII autoactivates into FXIIa, also called factor XII fragment(XIIf). Once small amounts of kalikrein are formed a positive feedback loop is active leading to enhanced conversion into FXIIa. The activation leads to a series of active enzyme formation. FXIIa converts prekallikrein to kallikrein and kallikrein digests kinogen to liberate proinflammatory bradykinin. Bradykinin triggers inflammatory reactions via activating endothelial cells resulting in vasodilatation, increased vascular permeability and production of other mediators like nitric oxide. The contact system has the ability to activate the complement system via the classical pathway. Simultaneous activation of both systems may lead to pathological conditions, like hereditary angioedema in individuals with dysfunctional C1-inhibitor (C1-IHB). FXIIa can activate complement protein C1r and to a lesser degree C1s in absence of C1-IHB. This leads to unimpeded bradykinin formation resulting in angioedema. Other interactions with complement system are found on the level of gC1qR and MASP-1. The antibody is specific for the heavy chain of FXIIa.

LL-37/CAP-18, Human, mAb 1-1C12, Hycult Biotech, HM2071

The monoclonal antibody 1-1C12 recognizes free LL-37 as well as its precursor human CAP18 (hCAP18). hCAP18 is a cathelicidin protein of ~18 kDa. It belongs to the cathelicidin family of antimicrobial peptides that are characterized by a conserved N-terminal cathelin domain and a variable C-terminal antimicrobial domain. Cathelicidins are predominantly found in the peroxidase-negative granules of neutrophils. During bacterial infections, the life span of neutrophils is regulated by various pathogen- and host-derived substances. Within the neutrophils, the cathelicidins are synthesized as preproproteins. After removal of the signal peptide,they are stored in granules as inactive proforms. The C-terminal antimicrobial peptides are activated when cleaved from the proforms of the cathelicidins by serine proteases from azurophil granules. hCAP18 is a major protein in specific granules of neutrophils, but it is also present in subpopulations of lymphocytes and monocytes, in squamous epithelia (of the mouth, tongue, esophagus, cervix, and vagina), pulmonary epithelium, keratinocytes in inflammatory skin diseases and in the epididymus. The antibacterial C-terminus of hCAP18, LL-37 (37 amino acids), has been shown to exert broad antimicrobial activity towards gram-negative as well as gram-positive bacteria and to have synergistic antibacterial effects with the defensins. For instance deficiency in saliva, LL-37 accords with occurrence of periodontal disease in patients with morbus Kostmann. LL-37 does not only kill bacteria, but can also modulate (suppress) neutrophil apoptosis via the activation of FPRL1 and P2X7 in bacterial infections. Suppression of neutrophil apoptosis results in the prolongation of their life span, and may be advantageous for host defense against bacterial invasion. Moreover it functions as a chemotactic agent for neutrophils, monocytes and T cells. LL-37 is markedly resistant to proteolytic degradation and to a limited extent also cytotoxic towards mammalian cells.

Solute Carrier Family 37 Member 2 (SLC37A2) Antibody, Abbexa, abx237957

SLC37A2 Antibody is a Rabbit Polyclonal against SLC37A2.

Rat Cell Division Cycle 37 (CDC37) ELISA Kit, Abbexa, abx505852

Rat Cell Division Cycle 37 (CDC37) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Rat Hsp90 co-chaperone Cdc37 concentrations in tissue homogenates, cell lysates and other biological fluids.

Solute Carrier Family 25 Member 37 (SLC25A37) Antibody, Abbexa, abx334294

SLC25A37 Antibody is a Rabbit Polyclonal against SLC25A37.

Anti-RIP2 antibody [EPR26079-37] - BSA and Azide free, Abcam, AB303555

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

Human Tetratricopeptide Repeat Protein 37 (TTC37) ELISA Kit, Abbexa, abx384014

Human Tetratricopeptide Repeat Protein 37 (TTC37) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human TTC37 concentrations in tissue homogenates, cell lysates and other biological fluids.

Solute Carrier Family 37 Member 1 (SLC37A1) Antibody, Abbexa, abx237956

SLC37A1 Antibody is a Rabbit Polyclonal against SLC37A1.

Anti-Sodium/calcium exchanger 2 antibody [EPR25106-37], Abcam, AB300455

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .